Skip to Content

Symlin Approval History

  • FDA approved: Yes (First approved March 16th, 2005)
  • Brand name: Symlin
  • Generic name: pramlintide acetate
  • Dosage form: Injection
  • Company: Amylin Pharmaceuticals, Inc.
  • Treatment for: Diabetes, Type 1, Diabetes, Type 2

Symlin (pramlintide acetate) is an antihyperglycemic drug for use in patients with diabetes treated with insulin.

Development History and FDA Approval Process for Symlin

Oct  1, 2007Approval FDA Approves Symlin Pen-Injector Devices Offering Convenience andAccuracy for Symlin Use
Mar 16, 2005Approval Symlin Amylin Pharmaceuticals, Inc. - Treatment for Diabetes in conjunction with insulin
Sep 30, 2004Amylin Pharmaceuticals Submits Complete Response to FDA for Symlin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.